Every Form 4 that Verastem, Inc. (VSTM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VSTM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSTM filings page.
Verastem, Inc. President and CEO Dan Paterson reported selling 1,302 shares of common stock on 2026-08-03 at $5.81 per share. According to a footnote, these shares were sold to satisfy statutory withholding requirements related to the vesting of restricted stock units. Following the transaction, he directly owns 589,940 shares of common stock. The transaction is affirmed as conducted under a Rule 10b5-1 trading plan.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 20,871 shares of common stock at $4.18 per share. According to the footnote, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, rather than a discretionary trade. Following the transaction, he directly owns 591,242 shares of Verastem common stock.
Verastem, Inc. Chief Financial Officer Daniel Calkins reported selling 4,089 shares of common stock. The transactions on June 22, 2026 consisted of open-market sales of 57 shares at $4.13 per share and 4,032 shares at $4.18 per share.
According to the footnote, these sales were made to satisfy statutory withholding requirements tied to the vesting of restricted stock units, meaning they were compensation-related rather than discretionary portfolio trades.
BAILEY MICHAEL P reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michael P. Bailey reported an equity award of 108,000 shares of Common Stock in the form of restricted stock units at no cash cost. The grant consists of 36,000 RSUs as an annual grant and 72,000 RSUs as an initial grant under Verastem's Amended and Restated 2021 Equity Incentive Plan.
The 36,000 annual grant RSUs vest in twelve monthly installments from June 2026 through May 2027, tied to continued board service. The 72,000 initial grant RSUs vest in twelve quarterly installments starting on May 21, 2026, and are scheduled to fully vest three years from that date, also contingent on continued service. Following this award, Bailey directly holds 108,000 shares/RSUs.
Tollefson Karin Anna reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Karin Anna Tollefson received a grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were awarded under Verastem’s Amended and Restated 2021 Equity Incentive Plan and require her continued service as a director to vest.
The RSUs vest in 12 substantially equal monthly installments, with the first 11 vesting on the last day of each month from June 2026 through April 2027. The final installment vests on the earlier of the day before Verastem’s 2027 Annual Meeting of Stockholders or May 31, 2027. After this grant, Tollefson directly holds 52,666 shares of Verastem Common Stock, including the granted RSUs.
Stuglik Brian M reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Brian M. Stuglik received an equity grant of 36,000 restricted stock units (RSUs) of Common Stock. The RSUs were granted at no cash cost as director compensation and will vest in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to continued board service. Following this award, Stuglik holds 137,147 shares of Verastem Common Stock directly.
Rowinsky Eric K reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Eric K. Rowinsky received a grant of 36,000 restricted stock units (RSUs). The grant was made at a price of $0.00 per share under Verastem’s Amended and Restated 2021 Equity Incentive Plan, reflecting stock-based compensation rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock. The RSUs vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholders’ meeting or May 31, 2027, contingent on his continued board service. Following this award, Rowinsky directly holds 52,666 shares of Verastem common stock.
ROBERTSON MICHELLE reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Michelle Robertson received a grant of 36,000 restricted stock units (RSUs) of Common Stock as equity compensation. The award was granted at no cash cost per share and is structured to vest over time rather than all at once.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock. The units vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 Annual Meeting of Stockholders or May 31, 2027, subject to her continued board service. After this grant, Robertson directly holds 52,666 shares of Verastem common stock.
Kapur Anil reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Anil Kapur received a grant of 36,000 restricted stock units (RSUs). The award was made at no cash cost per share and increased his directly held common stock-related position to 52,666 shares as reported after the transaction.
The RSUs were granted under Verastem’s Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of common stock, vesting in twelve substantially equal monthly installments from late June 2026 through April 2027, with the final installment vesting by May 31, 2027, if he continues serving as a director.
Bunn Paul A. reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director Paul A. Bunn received an equity grant of 36,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Amended and Restated 2021 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.
Each RSU represents one share of Common Stock. The award vests in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting on the earlier of the day before the 2027 annual stockholder meeting or May 31, 2027, subject to his continued board service. After this grant, Bunn holds 44,333 shares directly.
JOHNSON JOHN reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director John Johnson reported receiving a grant of 36,000 restricted stock units (RSUs) of Common Stock at no cash cost as equity compensation. Following this award, he holds 52,666 shares directly.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan. They vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting before the 2027 Annual Meeting of Stockholders or by May 31, 2027, as long as he continues serving as a director on each vesting date.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 806 shares of common stock at $5.82 per share. After the transaction, he directly holds 612,113 shares of Verastem common stock.
The filing explains that the sale was made to satisfy statutory withholding requirements arising from the vesting of restricted stock units, indicating it was a tax-related transaction tied to equity compensation rather than a discretionary reduction of his overall stake.
Calkins Daniel reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc.’s Chief Financial Officer Daniel Calkins received a grant of 57 shares of common stock on March 20, 2026 at a value of $5.74 per share. This was a compensation-related award, not an open-market purchase. Following the grant, he directly holds 121,327 common shares.
Verastem, Inc. President and CEO Dan Paterson reported a small sale of company stock tied to tax withholding. On February 4, 2026, he sold 970 shares of common stock at $6.69 per share to satisfy statutory withholding for vested restricted stock units.
After this transaction, Paterson directly held 612,919 shares of Verastem common stock, indicating he retains a substantial equity stake despite the routine tax-related sale.
Verastem, Inc. Chief Financial Officer receives equity grant in the form of 16,665 shares of Common Stock on January 21, 2026, reported at a price of $0.00 per share as an award, not an open-market purchase. These shares arise from restricted stock units (RSUs) granted under Verastem's Amended and Restated 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Common Stock.
The RSUs vest in three equal annual installments of approximately 33.3% on each of the first three anniversaries of January 21, 2026, becoming fully vested on January 21, 2029, as long as the CFO continues to serve as an employee or other service provider on each vesting date. Following this grant, the CFO directly beneficially owns 121,384 shares of Verastem common stock.
Verastem, Inc. reported an equity award to its President and CEO, Dan Paterson. On January 21, 2026, he was granted 213,785 shares of Verastem common stock in the form of restricted stock units (RSUs) at a price of $0.00 per share under the company’s Amended and Restated 2021 Equity Incentive Plan. Following this grant, he beneficially owns 613,889 shares of common stock directly.
The RSUs are scheduled to vest over three years. They vest as to 33.3% of the award on each of the first three anniversaries of January 21, 2026, so that the grant is fully vested on January 21, 2029. Vesting requires that Paterson continue to serve as an employee or other service provider to Verastem on each vesting date.
Verastem, Inc. reported an insider share sale by its President and CEO, Dan Paterson. On January 12, 2026, he sold 10,321 shares of Verastem common stock at a price of $7.16 per share.
According to the disclosure, this sale was made to satisfy statutory tax withholding requirements tied to the vesting of restricted stock units, meaning it was connected to equity compensation rather than an open-market discretionary sale. After this transaction, Paterson beneficially owned 400,104 shares of Verastem common stock directly.
Verastem, Inc. Chief Financial Officer Form 4 filing reports a small, routine sale of company stock tied to equity compensation. On January 12, 2026, the CFO, Daniel Calkins, sold 5,039 shares of Verastem common stock at $7.16 per share. According to the footnote, this sale was made to satisfy statutory withholding tax requirements in connection with the vesting of restricted stock units, rather than as a discretionary sale of shares.
Following this transaction, the reporting person beneficially owned 104,719 shares of Verastem common stock, held directly. The filing is made by a single reporting person in the capacity of Chief Financial Officer and reflects standard administration of equity awards.
Verastem, Inc. reported an insider equity award for Michael Kauffman, who serves as both a director and President of Development. On January 6, 2026, he received a stock option covering 200,000 shares of Verastem common stock with an exercise price of $6.88 per share, held directly.
The option vests over three years: 33.33% of the shares vest on the first anniversary of the January 6, 2026 grant date, and an additional 8.33% vest at the end of each three‑month period thereafter until the third anniversary. Vesting requires that Kauffman continue to serve as an employee or other service provider to Verastem on each vesting date.
Verastem, Inc. director reports small share sale for tax withholding
A Verastem, Inc. director reported selling 592 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the director beneficially owns 101,147 shares of Verastem common stock in direct form.
The filing explains that the shares sold were used to satisfy statutory tax withholding obligations that arose when restricted stock units vested, meaning the transaction relates to equity compensation rather than a discretionary open‑market sale of the director’s investment position.
Verastem, Inc. reported that its President and CEO, who also serves as a director, carried out a small sale of company stock. On 12/16/2025, the executive sold 393 shares of Verastem common stock at a price of $9.14 per share. According to the filing, this sale was made to satisfy statutory withholding requirements related to the vesting of restricted stock units, meaning it was tied to equity compensation rather than an open-market portfolio decision. After this transaction, the executive still beneficially owns 410,425 shares of Verastem common stock, held directly.
Verastem, Inc. director reports small stock sale for tax withholding
A director of Verastem, Inc. (VSTM) reported the sale of 283 shares of common stock on 12/16/2025 at a price of $9.14 per share. After this transaction, the reporting person beneficially owns 41,678 shares of Verastem common stock in direct ownership. According to the footnote, the sale was made to cover statutory tax withholding obligations related to the vesting of restricted stock units, rather than as a discretionary open-market sale.
Verastem, Inc. reported that its President and CEO, who is also a director, sold common stock in two transactions under a Rule 10b5-1 trading plan.
On December 10, 2025, the insider sold 2,000 shares of Verastem common stock at $10.07 per share, and on December 11, 2025, sold another 2,000 shares at $10.00 per share. Following these sales, the insider directly beneficially owned 410,818 shares of Verastem common stock.
Verastem, Inc. (VSTM) director reports option exercise and share sale. On 11/21/2025, the reporting person exercised stock options for 6,250 shares of common stock at an exercise price of $3.27 per share and sold 6,250 common shares at a weighted average price of $10.00 per share under a Rule 10b5-1 trading plan. Following these transactions, the reporting person held 8,333 shares of Verastem common stock directly and 6,250 stock options directly.
Verastem, Inc. (VSTM) director reported an open-market sale of common stock. On 11/21/2025, the reporting person sold 8,550 shares of Verastem common stock at a weighted average price of $10.00 per share, with individual trades executed between $10.00 and $10.01. The sales were made under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a set schedule. After these transactions, the reporting person beneficially owns 8,666 shares of Verastem common stock directly.
Verastem, Inc. (VSTM) reported insider stock sales by its President and CEO, who is also a director. The reporting person sold 2,000 shares of common stock on each of 11/21/2025, 11/24/2025, and 11/25/2025, all at a price of $10 per share. These transactions are marked with transaction code "S," indicating open market or private sales.
After these sales, the reporting person beneficially owned 432,818 shares of Verastem common stock directly. The filing notes that the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person, which is intended to provide an affirmative defense for trading while limiting discretion over the timing and amount of trades.
Verastem (VSTM) disclosed insider transactions by its President and CEO, reported as a director and officer. On 11/03/2025, the reporting person sold 1,299 shares at $9.35 to satisfy statutory tax withholding tied to RSU vesting, and separately sold 2,000 shares at $10.00 pursuant to a Rule 10b5-1 trading plan. Following these transactions, the reporting person beneficially owned 438,818 shares, held directly.
Verastem, Inc. (VSTM): Director insider sale filed on Form 4. On 10/09/2025, the reporting person, a director, sold 8,333 shares of common stock in open-market transactions at a weighted average price of $9.06 per share under a Rule 10b5-1 trading plan. The trades occurred across prices ranging from $8.70 to $9.33. Following the transaction, the reporting person directly owned 8,333 shares.
Insider sale to cover tax withholding: Verastem, Inc. CFO Daniel Calkins reported two small sales of common stock tied to restricted stock unit vesting. On 09/22/2025 he sold 57 shares at $9.08 and on 09/24/2025 he sold 25 shares at $9.23, reducing his beneficial ownership from 109,920 to 109,838 shares. The Form 4 states these sales were made to satisfy statutory withholding obligations associated with RSU vesting, not an open-market disposition for other purposes.